Pan-cancer analysis reveals the potential of hyaluronate synthase as therapeutic targets in human tumors.
Extracellular matrix
Glioblastoma multiforme
Hyaluronate synthase
Immune
Pan-cancer
Prognosis
Tumor microenvironment
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
28
05
2023
revised:
08
08
2023
accepted:
10
08
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
Hyaluronic acid (HA) is a crucial component of the extracellular matrix, and its level of accumulation is related to the progression of various malignant tumors. In this study, a pan-cancer analysis of the three enzymes called hyaluronan synthases (HAS1, HAS2, and HAS3) that produce HA was performed. The study comprehensively describes the characteristics of HAS1, HAS2, and HAS3 in cancers using public databases and tools, to identify the potential biological pathways involved at the molecular, protein, cellular, and clinical sample levels. The analysis showed that dysregulation of the three genes often occurs in cancer, contributing to cancer progression, metastasis, and prognosis. Overexpression of HAS2 promotes secretion of HA in GBM and enhances cell proliferation and migration. The common and specific functions of HAS in certain diseases have important research implications for the treatment and prognosis of tumors.
Identifiants
pubmed: 37636435
doi: 10.1016/j.heliyon.2023.e19112
pii: S2405-8440(23)06320-X
pmc: PMC10448108
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e19112Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Oncogene. 2013 Sep 12;32(37):4355-65
pubmed: 23108409
Nat Rev Cancer. 2006 Aug;6(8):583-92
pubmed: 16862189
Oncogene. 2018 Jun;37(24):3317-3328
pubmed: 29559744
Nucleic Acids Res. 2015 Jan;43(Database issue):D512-20
pubmed: 25514926
BMC Cancer. 2010 Sep 27;10:512
pubmed: 20875124
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612
pubmed: 33237311
Cancer Res. 2012 Jan 15;72(2):537-47
pubmed: 22113945
Front Immunol. 2015 Apr 14;6:169
pubmed: 25926834
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Glycobiology. 2015 Aug;25(8):825-35
pubmed: 25882295
BMC Genomics. 2015 Aug 26;16:636
pubmed: 26306699
Biomolecules. 2021 Oct 15;11(10):
pubmed: 34680150
Breast Cancer Res Treat. 2014 Jan;143(2):277-86
pubmed: 24337597
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Vet Sci. 2018 Nov 30;19(6):735-743
pubmed: 30041292
Nucleic Acids Res. 2019 Jul 2;47(W1):W561-W565
pubmed: 31114869
Gastroenterology. 2022 Jun;162(7):2047-2062
pubmed: 35271824
Cancer Cell Int. 2022 Dec 29;22(1):421
pubmed: 36581895
FEBS J. 2019 Aug;286(15):2883-2908
pubmed: 30724463
J Med Internet Res. 2021 Jul 26;23(7):e27633
pubmed: 34309564
Front Immunol. 2021 Oct 20;12:758648
pubmed: 34745134
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275